BMS-754807

Catalog No.S1124

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Cited by 6 Publications

Clin Cancer Res, 2013, 19(11):2984-94

PubMed: 23549869 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(7):1182-96

PubMed: ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Brain Res, 2018, 1678:407-418

PubMed: 29137974 ( click the link to review the publication )

PLoS One, 2015, 10(5):e0126867

PubMed: 25962155 ( click the link to review the publication )

1 Customer Review

Clin Cancer Res 2013 19(11), 2984-94. BMS-754807 purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Features

Muti-inhibitor of the IGR-1R/IR family.

Targets

Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	Met ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)	View More
1.7 nM	1.8 nM	4.1 nM	5.6 nM	7.4 nM	View More

In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). ^[1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. ^[2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Formulation	Activity Description	PMID
IGF-Sal	NVPDcHdkU2mwYYPlJIF{e2G7			MXjpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEmJRj2xVkApUUN3MDC9JFE{dk1rIHHu[EB1cGViZH;3cpN1emWjbTD0ZZJo\XS\|IFHreEApUUN3MDC9JFIzdk1rIHHu[EBOSVCNIDjJR\|UxKD1iMUPuUUk>	NEn6WlYyQTd5OECyOC=>
IGF-Sal	M4HLOmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7			M{nBSmlEPTB;NzDuUS=>	MWWxPVc4QDB{NB?=
CCRF-CEM (ALL)	MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3\JXp42KM7:TR?=	M4Pud2ROW09?	NX24emg{UUN3ME2xMlI{QSEQvF2=	MXKxPVk6PjJ5Mh?=
PC3	M1rSXmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NHnjN4h,PSEQvF2=	MUXEUXNQ	MWLJR\|UxRTBwOU[1JO69VQ>?	M{LTe\|E6QTl4Mkey
JD	Mlu3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NEXCNI9,PSEQvF2=	NUDORW1[TE2VTx?=	MWDJR\|UxRTBwM{mxJO69VQ>?	Mnu3NVk6QTZ{N{K=
DU145	NEfkVoZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYf+OUDPxE1?	M1uz[2ROW09?	MV;JR\|UxRTFwNE[1JO69VQ>?	MXyxPVk6PjJ5Mh?=
KAG	MmPkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFjjd4d,PSEQvF2=	MljzSG1UVw>?	NGDVU3BKSzVyPUGuOlY2KM7:TR?=	Mn\PNVk6QTZ{N{K=
K-562 (CML)	MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3jpSp42KM7:TR?=	NYPxNpFUTE2VTx?=	NX\5NlhMUUN3ME2yMlMxOiEQvF2=	NGGzcFkyQTl7NkK3Ni=>
B6-P210 (Murine ALL)	Ml;tS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MofCglUh\|ryP	MVfEUXNQ	NVzPWph2UUN3ME2xMlI6OyEQvF2=	NHHzVXIyQTl7NkK3Ni=>
LN CAP-FGC	NFmzc\|FIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFPFPYZ,PSEQvF2=	MVnEUXNQ	M2jnT2lEPTB;MT60N\|Qh\|ryP	NEnBZWwyQTl7NkK3Ni=>
VW	MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{ezZZ42KM7:TR?=	NGfqTHlFVVOR	NGnvUVFKSzVyPUCuNFE6KM7:TR?=	MVuxPVk6PjJ5Mh?=
MV411 (B Myelomonocytic)	NUjDZYh7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NF7EeJp,PSEQvF2=	NVTacWVoTE2VTx?=	MkXkTWM2OD1yLkOzJO69VQ>?	MlPINVk6QTZ{N{K=
MDA-PCa-2b	M3KyVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmrQglUh\|ryP	NVLWc41kTE2VTx?=	NGHKW2lKSzVyPUCuNFk5KM7:TR?=	M4\DS\|E6QTl4Mkey
LG	NVXIOFdpT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NV7tbGw1hjVizszN	NWTvSVhpTE2VTx?=	NGO3[IlKSzVyPUCuNFM5KM7:TR?=	MoT0NVk6QTZ{N{K=
RS411 (B cell precursor-ALL)	NXv0cmxlT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3:3d542KM7:TR?=	NGXFNI1FVVOR	MX;JR\|UxRTBwMUCyJO69VQ>?	NH\EW4gyQTl7NkK3Ni=>
22-r-1	M1nIOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2T4Zp42KM7:TR?=	NX3VPZYzTE2VTx?=	MlPITWM2OD1yLkG3OUDPxE1?	NXrNU\|l2OTl7OU[yO\|I>
5838	M4fCWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUn+OUDPxE1?	MXfEUXNQ	M2S4N2lEPTB;MD6wN\|Qh\|ryP	NVrnT4tlOTl7OU[yO\|I>
P388 (Murine)	NETURo9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{DRTp42KM7:TR?=	NX7SVm42TE2VTx?=	NYr1V5BkUUN3ME20MlI4KM7:TR?=	M2HyXFE6QTl4Mkey
A2780/S	M33CPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2frcJ42KM7:TR?=	NEW3W2ZFVVOR	MlfxTWM2OD1yLkGyNkDPxE1?	NWf1ZVVLOTl7OU[yO\|I>
RDES	Mnr0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mlr1glUh\|ryP	M{m0T2ROW09?	M4PpbWlEPTB;MD6wNVIh\|ryP	MnTxNVk6QTZ{N{K=
B6-T315I (Murine B-ALL)	MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Ml;kglUh\|ryP	MoDVSG1UVw>?	M{\aXWlEPTB;Mj64N{DPxE1?	NGXJXY0yQTl7NkK3Ni=>
TOV 112D	MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MWD+OUDPxE1?	Mlf5SG1UVw>?	M2LP[2lEPTB;Mj6xOFYh\|ryP	NXe3cnVwOTl7OU[yO\|I>
TC32	MojqS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MlPnglUh\|ryP	MWrEUXNQ	M1fiTmlEPTB;MD6wNFgh\|ryP	M{CxXFE6QTl4Mkey
HL60 (acute myelocytic)	NHvTdVdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYr+OUDPxE1?	MVzEUXNQ	NWiyZpRCUUN3ME2wMlEzKM7:TR?=	NI\aT2syQTl7NkK3Ni=>
TOV 21G	MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MWf+OUDPxE1?	Ml;ESG1UVw>?	MlPtTWM2OD12LkK3PUDPxE1?	NWrLRnVvOTl7OU[yO\|I>
TC71	NVfzeYJ3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NGjWRnl,PSEQvF2=	MYrEUXNQ	MWLJR\|UxRTBwMEG0JO69VQ>?	M{DmZlE6QTl4Mkey
HPN-ALL (T-cell)	MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEDNcIR,PSEQvF2=	MVXEUXNQ	NETI[W1KSzVyPUCuOVIh\|ryP	M1PINlE6QTl4Mkey
A2780R	NFTIXpdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFHkSlJ,PSEQvF2=	NHq5SGJFVVOR	M1n4SGlEPTB;MT61OlQh\|ryP	NFXJU28yQTl7NkK3Ni=>
Rh1	MnLhS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUH+OUDPxE1?	M3vvUGROW09?	NXX0Zph3UUN3ME2wMlAzPyEQvF2=	Ml65NVk6QTZ{N{K=
Kasumi-1 (acute myeloid)	MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mo\nglUh\|ryP	NIrHVGpFVVOR	NYezbnh5UUN3ME2wMlE3KM7:TR?=	Mn6yNVk6QTZ{N{K=
sk-ov-3	NGn4[m9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M13UeJ42KM7:TR?=	NF;BOI5FVVOR	MknQTWM2OD13LkGg{txO	MlPNNVk6QTZ{N{K=
ME	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVX+OUDPxE1?	NFrvS\|VFVVOR	M33xWWlEPTB;MD6wNVUh\|ryP	M2LTdFE6QTl4Mkey
L1210 (Murine lymphocytic)	M4q3OWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NX;2SINHhjVizszN	MVvEUXNQ	M4LBXWlEPTB;Mj6zPUDPxE1?	MV:xPVk6PjJ5Mh?=
sw-626	MlHNS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2fsS542KM7:TR?=	Mnv5SG1UVw>?	MnnGTWM2OD1{LkOwOkDPxE1?	MnexNVk6QTZ{N{K=
CTR	MnTxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX;+OUDPxE1?	NFPIUXlFVVOR	M2TOWWlEPTB;MD6yOVMh\|ryP	MkfGNVk6QTZ{N{K=
ML2 (Myelomonocytic)	NHPmVlVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXvM[m01hjVizszN	MYrEUXNQ	MkTGTWM2OD1yLkC5JO69VQ>?	MlXaNVk6QTZ{N{K=
ovcar-3	NXG5PJFrT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3\MOJ42KM7:TR?=	MX;EUXNQ	M1zOWmlEPTB;NTFOwG0>	MUexPVk6PjJ5Mh?=
Rh36	NIrrfHBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1ziOJ42KM7:TR?=	MlLySG1UVw>?	MkLETWM2OD1zLkSzNkDPxE1?	MYSxPVk6PjJ5Mh?=
MOLM-13 (acute myeloid)	NUfKZm9GT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnPkglUh\|ryP	NX\ZbJQyTE2VTx?=	M3\ofGlEPTB;MD60NkDPxE1?	MXixPVk6PjJ5Mh?=
ovcar-4	NHLmUGZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFXER3V,PSEQvF2=	NXTIcFl{TE2VTx?=	M{\l[mlEPTB;MTFOwG0>	MkDoNVk6QTZ{N{K=
Rh41	MlvjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NV7hV\|UxhjVizszN	MVvEUXNQ	NELXbpBKSzVyPUCuNFA2KM7:TR?=	NHPRe\|QyQTl7NkK3Ni=>
Mutz 2 (acute myeloid)	NXHzOWtxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUn+OUDPxE1?	MnqzSG1UVw>?	MUTJR\|UxRTFwMUWg{txO	NEOxR5cyQTl7NkK3Ni=>
ovcar-5	M1LIfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NIe1bYR,PSEQvF2=	MnvoSG1UVw>?	M134[WlEPTB;MD6wOUDPxE1?	M1zDU\|E6QTl4Mkey
RD1	NEHQOIdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NI\mWIF,PSEQvF2=	MnLwSG1UVw>?	MmP2TWM2OD1yLkC2PEDPxE1?	Mk\tNVk6QTZ{N{K=
OCI-AML 2 (acute myeloid)	MX7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3nWcp42KM7:TR?=	M3nTNGROW09?	MUTJR\|UxRTNwM{Og{txO	NGe4WHgyQTl7NkK3Ni=>
786-O	MoHyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4O2WJ42KM7:TR?=	NIX2cFhFVVOR	NH[wXnRKSzVyPUGuOlQ4KM7:TR?=	M17DOFE6QTl4Mkey
A673	MonvS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnHxglUh\|ryP	MlXMSG1UVw>?	MUPJR\|UxRTBwNEC4JO69VQ>?	NF3BVHMyQTl7NkK3Ni=>
TALL-1 (T-cell)	M2OyUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1L0Xp42KM7:TR?=	MVPEUXNQ	M4TkeGlEPTB;MT6yPEDPxE1?	MkfkNVk6QTZ{N{K=
151-B	MYPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnHUglUh\|ryP	MYnEUXNQ	NX7RT5o3UUN3ME2yMlY4KM7:TR?=	MWCxPVk6PjJ5Mh?=
PFSK-1	M1jFWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUP+OUDPxE1?	NWHxSYVKTE2VTx?=	MWPJR\|UxRTBwMUOyJO69VQ>?	NF3sb5UyQTl7NkK3Ni=>
THP-1	Mmj2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M33CNZ42KM7:TR?=	NFLIUopFVVOR	NUn0XnI{UUN3ME22MlU5KM7:TR?=	MV:xPVk6PjJ5Mh?=
HEK293	Ml7iS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MkLzglUh\|ryP	NWHNVXU1TE2VTx?=	MXXJR\|UxRTBwOUG1JO69VQ>?	NHfzcoUyQTl7NkK3Ni=>
DAOY	NYDsdXJCT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnO1glUh\|ryP	NWHUWXZqTE2VTx?=	MknuTWM2OD1zLkm3PUDPxE1?	M4i0blE6QTl4Mkey
SET2	MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWW5UXB5hjVizszN	MYjEUXNQ	MWPJR\|UxRTBwMkm4JO69VQ>?	NYPTUHh{OTl7OU[yO\|I>
HTB-46	NXTCeXdLT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NFi1eJh,PSEQvF2=	NHvweHVFVVOR	NXfCTW15UUN3ME21MlI2KM7:TR?=	NF;ER\|AyQTl7NkK3Ni=>
SK-NAS	M4nUUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MV7+OUDPxE1?	NUTGUlNCTE2VTx?=	M2qzfmlEPTB;MD60PVch\|ryP	NVO5T4tQOTl7OU[yO\|I>
CTLL2	MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NX7RR243hjVizszN	MWHEUXNQ	NVey[lJkUUN3ME6xMlAxKM7:TR?=	NYP0SIF4OTl7OU[yO\|I>
HTB-47	NXzwUY93T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4nHWJ42KM7:TR?=	M{LIfWROW09?	NULUcItkUUN3ME2yMlA2PiEQvF2=	NGXDTlUyQTl7NkK3Ni=>
LAN-1	NGn1WGdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEHGXVR,PSEQvF2=	MVLEUXNQ	MljOTWM2OD1yLkC0JO69VQ>?	MmnkNVk6QTZ{N{K=
ST486	NW\PWI81T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIe2PY1,PSEQvF2=	NFja[3JFVVOR	MlPGTWM2OD1zLkG5JO69VQ>?	NH3SS3EyQTl7NkK3Ni=>
HS766T	M3Lo[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1vYVZ42KM7:TR?=	MYnEUXNQ	NEfsVYZKSzVyPUKuNFAyKM7:TR?=	MVqxPVk6PjJ5Mh?=
IMR-32	MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWPVdYtuhjVizszN	Mn[3SG1UVw>?	MlrrTWM2OD1yLkK2NUDPxE1?	M{X0fVE6QTl4Mkey
Daudi (Burkitt's)	MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NEnQbHR,PSEQvF2=	MXvEUXNQ	NWnGfoRiUUN3ME2yMlY{PyEQvF2=	NI[yVlAyQTl7NkK3Ni=>
Aspc-1	M{n4ZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVvpPFJZhjVizszN	MmT3SG1UVw>?	M{X0bmlEPTB;MD6zO\|kh\|ryP	MmDZNVk6QTZ{N{K=
SK-NSH	M{joXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkLxglUh\|ryP	MWXEUXNQ	MYTJR\|UxRTBwMUO5JO69VQ>?	MVWxPVk6PjJ5Mh?=
MEC-1 (Chronic B cell)	NVq5VJp2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUjDZ5BjhjVizszN	NIS0SIlFVVOR	NYr0eIhbUUN3ME2yMlY{PyEQvF2=	MWmxPVk6PjJ5Mh?=
Capan-2	M1\C[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUj1SnY5hjVizszN	MkjYSG1UVw>?	M{PXUmlEPTB;MT63O\|Qh\|ryP	NHm5[pEyQTl7NkK3Ni=>
SHSY5Y	NGTKbWpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4HYXZ42KM7:TR?=	MmnZSG1UVw>?	Mny3TWM2OD1yLkGwOkDPxE1?	MnX4NVk6QTZ{N{K=
U937 (Histioocytic)	MoTVS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX7+OUDPxE1?	MkjTSG1UVw>?	MV;JR\|UxRjVwMECg{txO	MX:xPVk6PjJ5Mh?=
Bxpc-1	NXjnVFZCT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MV;+OUDPxE1?	MkXySG1UVw>?	MXfJR\|UxRTFwOUK0JO69VQ>?	M{C2RVE6QTl4Mkey
Bxpc-3	MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnO5glUh\|ryP	NGnnbplFVVOR	NEnUNYRKSzVyPkWuNFAh\|ryP	MXOxPVk6PjJ5Mh?=
HTB-92	M1;vN2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFjHeHl,PSEQvF2=	NYPjd\|J6TE2VTx?=	NUDT[ll5UUN3ME2xMlAzKM7:TR?=	M3f4WVE6QTl4Mkey
OCI-LY10 (B-cell)	MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4XjSZ42KM7:TR?=	M2G4T2ROW09?	M2L2PWlEPTB;MD60OUDPxE1?	M3ezT\|E6QTl4Mkey
PANC-1	MkjTS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2DrcJ42KM7:TR?=	MU\EUXNQ	MkXKTWM2OD53LkCwJO69VQ>?	NUnJ[XU4OTl7OU[yO\|I>
To184.T	NUDZ[HZ4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MUT+OUDPxE1?	MVrEUXNQ	MWfJR\|UxRTBwNE[5JO69VQ>?	NFzDSZYyQTl7NkK3Ni=>
OCI-LY19 (B-cell)	M2T3NGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXrYcZlmhjVizszN	NF;jeIVFVVOR	NF3j[ZBKSzVyPUCuOEDPxE1?	MVqxPVk6PjJ5Mh?=
PANC-1 BM	NGH2TVdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVT+OUDPxE1?	NH;zWmpFVVOR	NILhVW9KSzVyPkWuNFAh\|ryP	MYSxPVk6PjJ5Mh?=
SA-4	MoHXS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXr+OUDPxE1?	MVrEUXNQ	MVrJR\|UxRTFwM{CxJO69VQ>?	MWOxPVk6PjJ5Mh?=
RPMI 8226	MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2C5Xp42KM7:TR?=	NFLJXoFFVVOR	Mkf3TWM2OD1zLkK5N{DPxE1?	MVGxPVk6PjJ5Mh?=
HPAF-II	NGDCXpZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2TRUp42KM7:TR?=	MV\EUXNQ	M3q0UmlEPTB;MD62OFQh\|ryP	NGS5Z2EyQTl7NkK3Ni=>
SHP-77	NYHleYRxT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmLYglUh\|ryP	MlP2SG1UVw>?	MU\JR\|UxRTFwOEi4JO69VQ>?	NInifW8yQTl7NkK3Ni=>
U266 B1	MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NHK5ZWh,PSEQvF2=	NELKO5BFVVOR	MWnJR\|UxRTFwNk[5JO69VQ>?	MnK4NVk6QTZ{N{K=
Hs700t	MoSxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M{HQe542KM7:TR?=	NH71b2FFVVOR	M2S0[mlEPTB;MD6yN\|Eh\|ryP	NYnVWVRZOTl7OU[yO\|I>
NCI-446	NXjTWlB7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUXCdZNLhjVizszN	NVPPTnJMTE2VTx?=	MYLJR\|UxRTFwMUW0JO69VQ>?	M1PmWlE6QTl4Mkey
H929	NGfU[npIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYH+OUDPxE1?	NYLXOnltTE2VTx?=	MVTJR\|UxRTBwMEG0JO69VQ>?	NXHxcHdpOTl7OU[yO\|I>
PL45	M4fWb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFjkSIt,PSEQvF2=	Mkm0SG1UVw>?	NUXQN3BNUUN3ME2yMlI2PSEQvF2=	MnrRNVk6QTZ{N{K=
NCI-H383	NWjuVncyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NWfuW2xKhjVizszN	MWfEUXNQ	Ml\VTWM2OD53LkCwJO69VQ>?	NFHpZ5YyQTl7NkK3Ni=>
JJN3	MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MlHRglUh\|ryP	MkSySG1UVw>?	MmXhTWM2OD1{LkSzN{DPxE1?	NXzBWlhKOTl7OU[yO\|I>
SU.86.86	MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWDDXI9VhjVizszN	MmfqSG1UVw>?	MljBTWM2OD1{Lk[3NkDPxE1?	MVKxPVk6PjJ5Mh?=
H1299	MkO5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2rVV542KM7:TR?=	NIfmXmFFVVOR	M1nrSGlEPTB-NT6wNEDPxE1?	MYSxPVk6PjJ5Mh?=
MDA-MB-468	MnvRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NF7zS4p,PSEQvF2=	MWXEUXNQ	NYHtUYNFUUN3ME2wMlUxPCEQvF2=	MX[xPVk6PjJ5Mh?=
SW1990	NGH4VIpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MoDnglUh\|ryP	NYLpcoZJTE2VTx?=	Mm\wTWM2OD1yLkiyOkDPxE1?	M{TPUVE6QTl4Mkey
Calu-6	M3f2dmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoPwglUh\|ryP	MVPEUXNQ	M1\HcmlEPTB-NT6wNEDPxE1?	NWjW[llLOTl7OU[yO\|I>
MDA-MB-231	NWmxW5d4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIDGZoV,PSEQvF2=	MX\EUXNQ	MnTCTWM2OD1zLk[0PEDPxE1?	NFXnbmMyQTl7NkK3Ni=>
SW-684	NFzzTpVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWrRZYwyhjVizszN	NX\JdINvTE2VTx?=	MoPzTWM2OD53LkCwJO69VQ>?	NEHWNnMyQTl7NkK3Ni=>
H209	NWO1U2t2T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnzpglUh\|ryP	NHPie\|dFVVOR	MY\JR\|UxRTFwMUmzJO69VQ>?	NIjQdowyQTl7NkK3Ni=>
MDA-MB-231T	MmPpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3H4TZ42KM7:TR?=	M{j2N2ROW09?	M2nzdGlEPTB-NT6wNEDPxE1?	M2LGU\|E6QTl4Mkey
HT1080/S	MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYjiS4FPhjVizszN	M37HR2ROW09?	NITI[ItKSzVyPUCuOVMyKM7:TR?=	M2O3RVE6QTl4Mkey
H526 0.044	MnnQS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYrOblhshjVizszN	NHO1dFFFVVOR	NULISZhlUUN3ME2wMlA1PCEQvF2=	MnH5NVk6QTZ{N{K=
DU4475 2.431	M2e2[Wdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUT+OUDPxE1?	M4HmPWROW09?	MXHJR\|UxRTJwNEOxJO69VQ>?	MnP4NVk6QTZ{N{K=
HCT116	NVfQW4E6T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NUXk[WpvhjVizszN	M4DvPWROW09?	MYnJR\|UxRTBwOEWyJO69VQ>?	M2jaR\|E6QTl4Mkey
M109	MoHkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1PBXp42KM7:TR?=	NHzNXGRFVVOR	M{H3[WlEPTB;MT6wOVUh\|ryP	M17LRVE6QTl4Mkey
BT549	M3;nWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVX6NodmhjVizszN	MkCySG1UVw>?	NWDqclhyUUN3ME2xMlY1PSEQvF2=	MVuxPVk6PjJ5Mh?=
HCT116/VM46	MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnLHglUh\|ryP	M{HWS2ROW09?	MUfJR\|UxRTFwN{CyJO69VQ>?	MnP2NVk6QTZ{N{K=
H460	M2Swfmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MWL+OUDPxE1?	NIHX[opFVVOR	Mmf2TWM2OD1yLke5OUDPxE1?	MYexPVk6PjJ5Mh?=
MCF-7	NXLCd\|RzT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4\CXp42KM7:TR?=	NF[0WpRFVVOR	MWTJR\|UxRTBwMEG2JO69VQ>?	MY[xPVk6PjJ5Mh?=
GEO	Mn33S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWX+OUDPxE1?	NETDUHNFVVOR	NYjleJRoUUN3ME2wMlM2PiEQvF2=	M2HsOlE6QTl4Mkey
H441 0.646	MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{mzWp42KM7:TR?=	MojHSG1UVw>?	M{TUXmlEPTB;MD62OFYh\|ryP	M1OxPFE6QTl4Mkey
MCF-7-807R	NHXtR29Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUjoTZFVhjVizszN	NFHJXnlFVVOR	NXTDOWhPUUN3ME2wMlQ6KM7:TR?=	Mo[zNVk6QTZ{N{K=
Colo205	NViwXoh1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M{LNZZ42KM7:TR?=	NH;Ub\|lFVVOR	NHTxbVhKSzVyPUCuNVA1KM7:TR?=	NIDaTocyQTl7NkK3Ni=>
H292	MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFLjR\|B,PSEQvF2=	MmLzSG1UVw>?	M2jUWWlEPTB;MD63PFgh\|ryP	MnHzNVk6QTZ{N{K=
BT474 (S)	MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Ml\hglUh\|ryP	M1rlNGROW09?	MXnJR\|UxRTJwNECzJO69VQ>?	MmPRNVk6QTZ{N{K=
HT-29	NEfEWpdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYjQcpFzhjVizszN	M3TXVWROW09?	NYLvPGltUUN3ME2yMlExOyEQvF2=	NWjCR5VKOTl7OU[yO\|I>
A549	NX;MemFFT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2T6U542KM7:TR?=	NH3TPGRFVVOR	NIXPPFBKSzVyPUCuOlc2KM7:TR?=	NXvqWId{OTl7OU[yO\|I>
BT474-M1	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NYHDZ5lWhjVizszN	NYe3eVhVTE2VTx?=	MUjJR\|UxRTJwM{[1JO69VQ>?	MWKxPVk6PjJ5Mh?=
SW480	M2j4Wmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVj+OUDPxE1?	MWHEUXNQ	MUPJR\|UxRjVwMECg{txO	MkTmNVk6QTZ{N{K=
L2987	MlPRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1:0fp42KM7:TR?=	MnPYSG1UVw>?	MYHJR\|UxRTBwNESyJO69VQ>?	MUSxPVk6PjJ5Mh?=
AU565	NIDafFRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFu1SGp,PSEQvF2=	M2XVb2ROW09?	NUDTdpFHUUN3ME20Mlk4KM7:TR?=	Mn3INVk6QTZ{N{K=
SW403	MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXr+OUDPxE1?	NV;1XWQ2TE2VTx?=	MUXJR\|UxRTBwMkKg{txO	M{Xl[\|E6QTl4Mkey
H1437	MkDsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYPTWIVChjVizszN	NWnwfZI2TE2VTx?=	M{\K[WlEPTB;MD61NlMh\|ryP	NIPGXWsyQTl7NkK3Ni=>
BT-20	MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3vBTZ42KM7:TR?=	M3rTeWROW09?	NUTGTGt{UUN3ME2zMlU3OiEQvF2=	M{D2VFE6QTl4Mkey
Colo320HSR	MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYn+OUDPxE1?	M{HDcmROW09?	NGKwW5lKSzVyPUCuNFEyKM7:TR?=	NGP6UHcyQTl7NkK3Ni=>
H2087	NH7zPXFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4H4V542KM7:TR?=	NWfndY0yTE2VTx?=	NEHCcopKSzVyPkGuNFAh\|ryP	MVSxPVk6PjJ5Mh?=
HCC1419	M{jMO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXLJSYlUhjVizszN	M2XpS2ROW09?	MUTJR\|UxRTJwNUG3JO69VQ>?	M4H6SFE6QTl4Mkey
WiDr	M4L4Xmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MluxglUh\|ryP	MYXEUXNQ	NX;RUlFRUUN3ME2wMlA4PiEQvF2=	M{Ow[FE6QTl4Mkey
H661 0.573	MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{D4Vp42KM7:TR?=	MV7EUXNQ	MUHJR\|UxRTBwNUezJO69VQ>?	M3;lOVE6QTl4Mkey
HCC-38	MX7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MlfnglUh\|ryP	MYHEUXNQ	NV7KNWhQUUN3ME61MlAxKM7:TR?=	M4\UO\|E6QTl4Mkey
LS174T	NUDUUodRT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXX+OUDPxE1?	MlfESG1UVw>?	NXfsfYxbUUN3ME2wMlU{PSEQvF2=	M4PXRVE6QTl4Mkey
H211	MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NV63bZlDhjVizszN	M4P1NWROW09?	NXrDe\|VZUUN3ME2wMlc{OyEQvF2=	MWmxPVk6PjJ5Mh?=
HCC70	NWG5U5JIT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Ml\BglUh\|ryP	M3;FcmROW09?	MlryTWM2OD1zLkW1JO69VQ>?	NVnpfGpLOTl7OU[yO\|I>
SW116	Ml7yS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NYTsRWR4hjVizszN	MnXOSG1UVw>?	NVf6R2VTUUN3ME2wMlA3PyEQvF2=	MmnwNVk6QTZ{N{K=
H513	NYrPWnJWT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M2\MXp42KM7:TR?=	NULBflJWTE2VTx?=	MkfkTWM2OD12LkS0PEDPxE1?	MoPmNVk6QTZ{N{K=
MDA-MB-157	MlXUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFW3VVZ,PSEQvF2=	NWPReVVOTE2VTx?=	MnXmTWM2OD1yLkCzOkDPxE1?	M3jVPVE6QTl4Mkey
H2052	NVvjTY1pT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NETYZpN,PSEQvF2=	NF3CZoRFVVOR	NX3j[41sUUN3ME2xMlA2KM7:TR?=	MlSyNVk6QTZ{N{K=
MDA-MB-415	NIHKNmRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVL6e4h{hjVizszN	NWfHOHRSTE2VTx?=	MXvJR\|UxRjVwMECg{txO	NH3TOpQyQTl7NkK3Ni=>
DLD-1	MlX3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUD+OUDPxE1?	MmjvSG1UVw>?	NYnUS5pYUUN3ME2wMlkxQSEQvF2=	NUPxVIdOOTl7OU[yO\|I>
H2595	M4m2NWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Ml3ZglUh\|ryP	NXywOGIxTE2VTx?=	NFrqXoxKSzVyPUSuOFc2KM7:TR?=	NG\KfVcyQTl7NkK3Ni=>
MDA-MB-435S	MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MWn+OUDPxE1?	MmO5SG1UVw>?	MUDJR\|UxRTFwOE[5JO69VQ>?	NFrUNZcyQTl7NkK3Ni=>
HCT15	Mk\tS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoL4glUh\|ryP	Mo[3SG1UVw>?	NHW1UnBKSzVyPkGuNFAh\|ryP	MnvRNVk6QTZ{N{K=
SK-Hep1	MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3PmdJ42KM7:TR?=	MWHEUXNQ	NUKwRmxwUUN3ME2wMlE1PiEQvF2=	MlLaNVk6QTZ{N{K=
MDA-MB-436	NFTVVJRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MkfMglUh\|ryP	M3SwNWROW09?	NG\Wd3JKSzVyPUWuOVAzKM7:TR?=	NFXZU5oyQTl7NkK3Ni=>
KM12C	NXvFUHV{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Mlr5glUh\|ryP	MoS0SG1UVw>?	NWSwXFh{UUN3ME2wMlA2PCEQvF2=	NX\MS4ZxOTl7OU[yO\|I>
HEPG2	NVPzPYN4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NEnjOWJ,PSEQvF2=	M1fCSWROW09?	NGL0OGRKSzVyPUCuNFI2KM7:TR?=	NWTkSG9jOTl7OU[yO\|I>
MDA-MB-453	NUjTXm9QT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXj+OUDPxE1?	M1TZTGROW09?	MYjJR\|UxRTFwOE[5JO69VQ>?	NXnzRo1mOTl7OU[yO\|I>
KM12SM	NHTLZmhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVj+OUDPxE1?	NUnqeHNPTE2VTx?=	M{jGOGlEPTB;MD6wOVkh\|ryP	MYSxPVk6PjJ5Mh?=
1483	NFrLPJdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3;CSZ42KM7:TR?=	MYjEUXNQ	M1m4SGlEPTB;Mj6xPUDPxE1?	NFvxVnQyQTl7NkK3Ni=>
Hs578t	MmPuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXr+OUDPxE1?	Mn;3SG1UVw>?	NISwOHFKSzVyPUGuNlg4KM7:TR?=	NEfUcXEyQTl7NkK3Ni=>
LS180	NFLicopIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M4HidZ42KM7:TR?=	M{TiS2ROW09?	MV;JR\|UxRTBwNkm2JO69VQ>?	MVmxPVk6PjJ5Mh?=
FaDu	MoLGS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MkjEglUh\|ryP	NHfTWmRFVVOR	MVzJR\|UxRTFwMkeg{txO	MXyxPVk6PjJ5Mh?=
ZR-75-1	M4rQZ2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVT+OUDPxE1?	M4G2c2ROW09?	NWrQRVBJUUN3ME2yMlA5PCEQvF2=	M4fsdFE6QTl4Mkey
LS513	NFTtUYhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{jDep42KM7:TR?=	M{Lm[mROW09?	Mmn2TWM2OD1yLkGzOUDPxE1?	NELJZZgyQTl7NkK3Ni=>
Detroit.562	NW\pPG4xT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYi2XllKhjVizszN	NXTURpY1TE2VTx?=	M{nKd2lEPTB;MT6xOEDPxE1?	MnjxNVk6QTZ{N{K=
ZR-75-30	M1zqSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4HJOp42KM7:TR?=	MVTEUXNQ	M3y1NmlEPTB-NT6wNEDPxE1?	NF;VNHUyQTl7NkK3Ni=>
RKO-PM	NH62SGdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{Lw[Z42KM7:TR?=	NEjjWWhFVVOR	NED4[llKSzVyPUCuNlMzKM7:TR?=	NFzFR2oyQTl7NkK3Ni=>
Cal.27	Mn;wS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYL+OUDPxE1?	Mm\SSG1UVw>?	NYTtTmo2UUN3ME2yJO69VQ>?	MX2xPVk6PjJ5Mh?=
KPL4	Mn3IS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1fVd542KM7:TR?=	NIPNNZRFVVOR	NGTtdFRKSzVyPUGuNlUzKM7:TR?=	NIfwboUyQTl7NkK3Ni=>
PKO-RM13	Mn;OS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NUnteHg2hjVizszN	M1S5dGROW09?	NV;z[mVRUUN3ME2wMlQzPSEQvF2=	MkL2NVk6QTZ{N{K=
HS.53.T	NWTzcpBOT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3XDbZ42KM7:TR?=	MmL2SG1UVw>?	NEW1bW5KSzVyPUCuO\|kh\|ryP	MWqxPVk6PjJ5Mh?=
EMT6	NX\CPYhkT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1O5WZ42KM7:TR?=	NGLvS4hFVVOR	NED5RWRKSzVyPUCuPFA3KM7:TR?=	NWizdXB4OTl7OU[yO\|I>
SNU-C1	NF64Wo1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmrWglUh\|ryP	NF;GcWdFVVOR	NXnodIl1UUN3ME2wMlAxPyEQvF2=	MmX0NVk6QTZ{N{K=
SQCCY1	NWHkWnk1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVL+OUDPxE1?	NVjIT2tuTE2VTx?=	MV3JR\|UxRTBwN{mg{txO	NWDlU2pHOTl7OU[yO\|I>
SW480	NYrZb29bT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIjtZ2R,PSEQvF2=	M3e4dGROW09?	Mmn3TWM2OD1yLkCzO{DPxE1?	MnW4NVk6QTZ{N{K=
SCC9	MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NIDp[It,PSEQvF2=	NVv4bpFxTE2VTx?=	M4jWTWlEPTB;MD63OUDPxE1?	NEjIcY4yQTl7NkK3Ni=>
SK-LMS-1	MkSxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MVz+OUDPxE1?	M3v2e2ROW09?	Ml;XTWM2OD1yLk[4O{DPxE1?	NV3adGx[OTl7OU[yO\|I>
SCC25	NVPaV\|dnT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4TXZZ42KM7:TR?=	NGe5[2dFVVOR	NFHlU21KSzVyPUCuOlgh\|ryP	NIHy[IYyQTl7NkK3Ni=>
U87	NHTXXmRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MYH+OUDPxE1?	MVjEUXNQ	MmnzTWM2OD1yLkm1JO69VQ>?	MoTwNVk6QTZ{N{K=
SCC15	Mn\6S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVXHRVRuhjVizszN	M1HGT2ROW09?	M37vfWlEPTB;MD62O{DPxE1?	NFXZUXgyQTl7NkK3Ni=>
T98G	M3viSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NIPYdm1,PSEQvF2=	MkHBSG1UVw>?	M12wOGlEPTB;MT6yNVgh\|ryP	M2rPUlE6QTl4Mkey
SCC4	MVLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MV3+OUDPxE1?	MVjEUXNQ	MofuTWM2OD1yLk[zJO69VQ>?	MUWxPVk6PjJ5Mh?=
U118	NX7IPFRUT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHz6cWN,PSEQvF2=	NYTPWJZ6TE2VTx?=	NYCwZ4pmUUN3ME2xMlYyQCEQvF2=	NWfleGluOTl7OU[yO\|I>
TU167	MkjDS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NE\sbIR,PSEQvF2=	NFrKb41FVVOR	MV7JR\|UxRTRwNUKg{txO	MVKxPVk6PjJ5Mh?=
NCI-H727	NIjkd3BIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M{HTVZ4yOOLCit88US=>	MYLEUXNQ	MkHFTWM2OD12Mkigcm0>	MUSyNFM5PTd2Nx?=
NCI-H720	Mn3uS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYH+NVDjiIsQvF2=	MXnEUXNQ	Mmj2TWM2OD1{Lkig{txO	M4nGZ\|IxOzh3N{S3
NCI-H835	NXzQWFJOT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIfaOWh,OTEkgJtOwG0>	NEHIcHZFVVOR	MoL4TWM2OD1zIN88US=>	MXKyNFM5PTd2Nx?=
NCI-H727	MUPLbY5ie2ViYYPzZZk>	NEnMWmN,OTEkgJtOwG0>	Mny3SG1UVw>?	NYjwR5VtcW6qaXLpeJMh[2:wc4TpeJV1cX[nIFnHSlFTKGG3dH;wbI9{eGixconsZZRqd25?	NGrPe4IzODN6NUe0Oy=>
RD	NV\keIZHT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVH+NVDjiIsQvF2=		NHq2fWNKSzVyPUGuNVIhyrWP	M3vMblIyOjl6N{S1
Rh41	NHnobllIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3rJbJ4yOOLCit88US=>		M3OzSWlEPTB;MD6wO{DDvU1?	M{XrSlIyOjl6N{S1
Rh18	NYHBd4xKT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVm0cnNShjFy4pEK{txO		NGDzO4lKSzVyPUSuPVYhyrWP	M122SlIyOjl6N{S1
Rh30	M1XRUGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MVv+NVDjiIsQvF2=		NUK1Spg2UUN3ME2wMlE6KML3TR?=	Mn64NlEzQTh5NEW=
BT-12	M1W4dWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NE\Id2x,OTEkgJtOwG0>		MoPxTWM2OD1yLke4JOK2VQ>?	NXvKbVBEOjF{OUi3OFU>
CHLA-266	M1zkdGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1u5OJ4yOOLCit88US=>		MYfJR\|UxRTBwOEmgxtVO	NGq1cY8zOTJ7OEe0OS=>
TC-71	M3z1c2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1f5eJ4yOOLCit88US=>		NGD0Z3RKSzVyPUCuNVEhyrWP	MWiyNVI6QDd2NR?=
CHLA-9	MUDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWXtTYc3hjFy4pEK{txO		MnHkTWM2OD1yLkGyJOK2VQ>?	M1KxZ\|IyOjl6N{S1
CHLA-10	NVPvXHd3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MWr+NVDjiIsQvF2=		M{LS[mlEPTB;MD62NkDDvU1?	MUWyNVI6QDd2NR?=
CHLA-258	NEi5PG5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXHLZmkzhjFy4pEK{txO		MnrRTWM2OD1yLkK3JOK2VQ>?	MYWyNVI6QDd2NR?=
GBM2	MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MlXDglEx6oDMzszN		NYnxR4ExUUN3ME2xMlQ4KML3TR?=	M1vxTVIyOjl6N{S1
NB-1643	M4H2dWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NGTPS2p,OTEkgJtOwG0>		MV7JR\|UxRTBwMUKgxtVO	MWqyNVI6QDd2NR?=
NB-EBc1	NW\uc\|NsT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnjLglEx6oDMzszN		NYTIbnZuUUN3ME2wMlM2KML3TR?=	MYmyNVI6QDd2NR?=
CHLA-90	MkLiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3jndJ4yOOLCit88US=>		NF3iWo5KSzVyPUCuO\|chyrWP	MYeyNVI6QDd2NR?=
CHLA-136	M{TNN2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M3ToTZ4yOOLCit88US=>		M{PBRWlEPTB;MD61NkDDvU1?	M{PsSFIyOjl6N{S1
NALM-6	MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MW\+NVDjiIsQvF2=		Mn7QTWM2OD1yLkS5JOK2VQ>?	M3vNWFIyOjl6N{S1
COG-LL-317	M{P4WWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MoXkglEx6oDMzszN		M3zNbGlEPTB;MT6zPEDDvU1?	MYSyNVI6QDd2NR?=
RS4;11	M1z5c2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NH;kUnN,OTEkgJtOwG0>		NHmwNlBKSzVyPUCuN\|ghyrWP	NVf5b5I3OjF{OUi3OFU>
MOLT-4	Ml7yS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NWq0NmFUhjFy4pEK{txO		MlH6TWM2OD1yLkWzJOK2VQ>?	M2XyOlIyOjl6N{S1
CCRF-CEM	MmHxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3i1cJ4yOOLCit88US=>		MnnrTWM2OD1zLkGzJOK2VQ>?	MnzhNlEzQTh5NEW=
Kasumi-1	Mnm3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mn;XglEx6oDMzszN		NXfuR\|duUUN3ME2xMlIhyrWP	MXyyNVI6QDd2NR?=
Karpas-299	NHGyeZlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	Ml:0glEx6oDMzszN		MmXoTWM2OD1zLk[0JOK2VQ>?	M17zVlIyOjl6N{S1
Ramos-RA1	NIq1N3VIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NFy1[WF,OTEkgJtOwG0>		NFXLSo5KSzVyPUGuN\|EhyrWP	MkLENlEzQTh5NEW=
Rh30	NETaVXRHfW6ldHnvckBie3OjeR?=			NHfV[nhqdmS3Y3XzJIFvKGmwY4LlZZNmKG:oIGPGT{BxcG:\|cHjvdplt[XSrb36=	MXmyOVkzPTN5OB?=
Rh41	NELySG9HfW6ldHnvckBie3OjeR?=			NX75RZY5cW6mdXPld{BidiCrbnPy[YF{\SCxZjDTSmsheGixc4Doc5J6dGG2aX;u	NXPJO3FNOjV7MkWzO\|g>
RD	M{D3NGZ2dmO2aX;uJIF{e2G7			M3e0OYlv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?=	Mn\xNlU6OjV\|N{i=
A549	MnPhT4lv[XOnIHHzd4F6	MWmwMlXjiIsQvF2=	MYXEUXNQ	M4ftPYlvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v	M2jNV\|I3QTJ6NUe4
NCI-H358	NIfjUGdMcW6jc3WgZZN{[Xl?	NFvXbJQxNjYkgJtOwG0>	NInT[HpFVVOR	M1\uPYlvcGmkaYTzJGlITi2LUj;JVkBi[3SrdnH0bY9v	NGOwNHYzPjl{OEW3PC=>
A549	MkfpSpVv[3Srb36gZZN{[Xl?	M3vkcFAvPeLCit88US=>	MorFSG1UVw>?	MYTjZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM	MYSyOlkzQDV5OB?=
NCI-H358	NWHLXI1lTnWwY4Tpc44h[XO\|YYm=	MnvaNE426oDMzszN	NUfubYh1TE2VTx?=	MVzjZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM	MV2yOlkzQDV5OB?=
A549	NFW1fVFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVP0fpAzhjFy4pEK{txO	MVnEUXNQ	MmfMTWM2OD1yLke2JO69VQ>?	M3\qO\|I3QTJ6NUe4
NCI-H358	MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFSxdZR,OTEkgJtOwG0>	NXOycXJNTE2VTx?=	MVXJR\|UxRTFwMEmg{txO	M2DPPVI3QTJ6NUe4
A549	NVO0OGpHSXCxcITvd4l{KGG\|c3H5	MVewMlXjiIsQvF2=	M3Xsd2ROW09?	Mnj4bY5lfWOnczDBdI9xfG:\|aYO=	NFyzXoszPjl{OEW3PC=>
NCI-H358	NEHpU\|hCeG:ydH;zbZMh[XO\|YYm=	MoHnNE426oDMzszN	M3;xOGROW09?	NEm4XpBqdmS3Y3XzJGFxd3C2b4Ppdy=>	NILSWIgzPjl{OEW3PC=>
A549	NXXNW\|d[TnWwY4Tpc44h[XO\|YYm=	MYCwMlXjiIsQvF2=	NIj2SZlFVVOR	NXr3Z5hnemWmdXPld{B4d3WwZDDjcI9{fXKn	NEn4T2UzPjl{OEW3PC=>
NCI-H358	M{fKfWZ2dmO2aX;uJIF{e2G7	MYKwMlXjiIsQvF2=	NGr3fohFVVOR	MVLy[YR2[2W\|IIfveY5lKGOub4P1doU>	M4fvNFI3QTJ6NUe4

... Click to View More Cell Line Experimental Data

In vivo

BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. ^[1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. ^[2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. ^[3]

Protocol

Kinase Assay:^[1]	+ Expand Kinase inhibition assays: The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to K_m ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:^[1]	+ Expand Cell lines: IGF-1R-Sal, RH41 and Geo cell lines Concentrations: 365 nM Incubation Time: 72 hours Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of ³H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol) Dosages: 150 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	92 mg/mL (199.35 mM)
	Ethanol	92 mg/mL (199.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BMS-754807 SDF

Molecular Weight	461.49
Formula	C₂₃H₂₄FN₉O
CAS No.	1001350-96-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01525823	Completed	Healthy Volunteers	Bristol-Myers Squibb	February 2012	Phase 1
NCT01525823	Completed	Healthy Volunteers	Bristol-Myers Squibb	February 2012	Phase 1
NCT01225172	Completed	Breast Cancer	Bristol-Myers Squibb\|Mayo Clinic	December 2010	Phase 2
NCT01225172	Completed	Breast Cancer	Bristol-Myers Squibb\|Mayo Clinic	December 2010	Phase 2
NCT00908024	Terminated	Colorectal Cancer\|Head and Neck Cancer\|Neoplasm Metastasis	Bristol-Myers Squibb	October 2009	Phase 1\|Phase 2
NCT00908024	Terminated	Colorectal Cancer\|Head and Neck Cancer\|Neoplasm Metastasis	Bristol-Myers Squibb	October 2009	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Selective IGF-1R Inhibitor

NVP-AEW541 : IGF-1R-selective, IC50=86 nM.
IGF-1R Inhibitor in Clinical Trial

OSI-906 (Linsitinib) : Phase II for Advanced Solid Tumors.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.
Classic IGF-1R Inhibitor

BMS-536924 : ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

Related IGF-1R Products4

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
Linsitinib (OSI-906)

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 6 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 6 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)